Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
Healthcare
$6.98 +1.28%
+$0.16 today
- Market cap
- $150.57M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
52W Low $11.40High $16.77
Volume 0.23M
Average 0.35M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$41.13M
FY 2025 · Annual
Investing Cash Flow
-$1.45M
FY 2025 · Annual
Financing Cash Flow
$42.57M
FY 2025 · Annual
Cash Flow Statement
USD
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$49.5M
+ D&A$323.0K
+ Stock-Based Comp$7.7M
- Deferred Tax-$142.0K
- Working Capital-$200.0K
+ Other Non-Cash$712.0K
= Operating Cash Flow-$41.1M
- Capex-$1.4M
= Free Cash Flow-$42.6M
Analysis
FY2025 free cash flow is -$42.6M. FCF conversion is 86.0% of net income. Operating cash flow was -$41.1M, with capex of -$1.4M. The largest bridge item is Stock-Based Comp at $7.7M.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 2, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 8-K/A | 8-K/A filing | Oct 9, 2026 |
Does RNA generate free cash flow?
Atrium Therapeutics, Inc. (RNA) generated -$42.57M of free cash flow in fiscal 2025.
How much operating cash flow does RNA produce?
Operating cash flow was -$41.13M, before capital expenditures of $1.45M.
Continue the stock analysis
Jump to another research area for this company.